Literature DB >> 8817299

Labour productivity effects of prescribed medicines for chronically ill workers.

J A Rizzo1, T A Abbott, S Pashko.   

Abstract

Previous work on the labour productivity effects of chronic illness has not separated the effects of chronic illnesses from the effects of prescription medications taken to alleviate these conditions. Using nationally representative observational data, this study estimates the pure effect of chronic illness, and the marginal effect of prescription medicines, on labour productivity. As Americans continue to scrutinize health care expenditures, such estimates will play an increasing role in determining the allocation of resources for medical treatments. Estimates are presented of the costs and benefits to employers of covering prescription medications for workers aged 18-64 years afflicted with specific chronic illnesses. The effects of prescription medicines on hourly wages and days lost from work are examined for four major chronic illnesses: hypertension, heart disease, non-insulin dependent (type II) diabetes and depression. The net benefits to employers from having workers take prescription medicines for their chronic illnesses are substantial. Assuming average compliance rates are achieved, net benefits to employers in 1987 amounted to $286 per hypertensive employee, $633 per employee with heart disease; $822 per depressed employee, and $1475 per type II diabetic employee under medication from a physician. These estimated benefits accrue because prescription medications substantially lower absenteeism among chronically ill workers.

Entities:  

Mesh:

Year:  1996        PMID: 8817299     DOI: 10.1002/(SICI)1099-1050(199605)5:3<249::AID-HEC203>3.0.CO;2-A

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  11 in total

1.  Household income losses associated with ischaemic heart disease for US employees.

Authors:  J Herrin; C B Cangialose; S J Boccuzzi; W S Weintraub; D J Ballard
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

Review 2.  Employers' benefits from workers' health insurance.

Authors:  Ellen O'Brien
Journal:  Milbank Q       Date:  2003       Impact factor: 4.911

Review 3.  Remission from depression : a review of venlafaxine clinical and economic evidence.

Authors:  Donald Han; Edward C Y Wang
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Uncontrolled diabetes and health care utilisation: panel data evidence from Spain.

Authors:  Joan Gil; Antoni Sicras-Mainar; Eugenio Zucchelli
Journal:  Eur J Health Econ       Date:  2017-08-10

5.  Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder.

Authors:  Alan M Langlieb; Christine J Guico-Pabia
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

6.  Effectiveness, safety and cost of drug substitution in hypertension.

Authors:  Atholl Johnston; Panagiotis Stafylas; George S Stergiou
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

7.  Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy.

Authors:  Gregory Hess; Jerrold Hill; Helen Lau; Homa Dastani; Paresh Chaudhari
Journal:  P T       Date:  2008-11

8.  Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study.

Authors:  Li Wang; Wenhui Wei; Raymond Miao; Lin Xie; Onur Baser
Journal:  BMJ Open       Date:  2013-04-30       Impact factor: 2.692

Review 9.  Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.

Authors:  Peter Bramlage; Joerg Hasford
Journal:  Cardiovasc Diabetol       Date:  2009-03-27       Impact factor: 9.951

10.  A controlled trial of value-based insurance design - the MHealthy: Focus on Diabetes (FOD) trial.

Authors:  Alicen Spaulding; A Mark Fendrick; William H Herman; James G Stevenson; Dean G Smith; Michael E Chernew; Dawn M Parsons; Keith Bruhnsen; Allison B Rosen
Journal:  Implement Sci       Date:  2009-04-07       Impact factor: 7.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.